Thermo Fisher Scientific's $13.6 Billion Acquisition of Life Technologies Boosts Flagging M&A Numbers May 01, 2013 | Press Release
Burrill Securities Launches Institutional Breakthrough Series April 29, 2013 | Press Release
Big Biotech Outpaces Big Pharma, Burrill & Company says April 16, 2013 | Press ReleaseSee all News
Dr. Redei is an Entrepreneur-in-Residence in the venture capital group with two decades of experience in healthcare technology, the pharmaceutical industry, and academia. He is a former University of California, San Francisco faculty member and holds an M.D., as well as a Ph.D. in Applied Neuroinformatics. He comes to Burrill & Company from Roche/Genentech, a leader in personalized healthcare.
Before joining Burrill, he headed clinical and imaging informatics at Roche for all six therapeutic areas globally, including CNS. At Roche, he was instrumental in developing a number of group-wide emerging IT strategies and implemented the company’s first forays into on-demand/cloud computing for clinical applications, and digital health. He also led the informatics effort of a consortium of five pharma companies to enable disease understanding, incorporating biosample, imaging, and clinical data sources from around the globe.